[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Atrium Therapeutics Inc (RNA)

Atrium Therapeutics Inc (RNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Income Statement for [[ item.sessionDateDisplayLong ]]

Fiscal Year End Date: 12/31

(Values in U.S. thousands)
  06-2021 03-2021 12-2020 09-2020 06-2020
Sales 2,607 2,704 2,142 1,746 1,541
Gross Profit 2,607 2,704 2,142 1,746 1,541
Operating Expenses 6,268 5,884 4,816 3,757 2,925
Operating Income -3,661 -3,180 -2,674 -2,011 -1,384
Interest Expense 0 0 0 0 131
Other Income -22,692 -20,664 -13,601 -9,428 -9,041
Pre-tax Income -26,353 -23,844 -16,275 -11,439 -10,556
Net Income Continuous -26,353 -23,844 -16,275 -11,439 -10,556
Net Income $-26,353 $-23,844 $-16,275 $-11,439 $-10,556
EBITDA(a) $-3,661 $-3,180 $-2,674 $-2,011 $-1,384
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.